San Francisco - Interim results of a phase 2,vehicle-controlled, bilateral study evaluating the efficacy andsafety of broad area topical 5-aminolevulenic acid (ALA, LevulanKerastick, DUSA Pharmaceuticals) photodynamic therapy (PDT) withvarious light sources show that ALA plus blue light (BLU-U, DUSAPharmaceuticals) was significantly more effective than vehicle plusblue light in improving facial photodamage, but the statisticalanalyses did not find ALA pretreatment enhanced the benefitsachieved using an intense pulsed light source (IPL; Quantum,Lumenis) or a pulsed dye laser (PDL; VStar, Cynosure), said RobertA. Weiss, M.D., associate professor of dermatology, Johns HopkinsUniversity School of Medicine, Baltimore, and an investigator inthe phase 2 trial.